Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.
- 15 June 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 97 (12), 2833-2841
- https://doi.org/10.1172/jci118739
Abstract
We have previously hypothesized that the pro-inflammatory cytokine TNF alpha has a pivotal role in the pathogenesis of rheumatoid arthritis (RA). It mediates its effects by cross-linking surface p55 TNF receptors (TNF-R), which can be proteolytically cleaved to yield soluble fragments. Upon binding TNF alpha soluble TNF-R (sTNF-R) can inhibit its function. We investigated the enzymatic nature of the proteases involved in TNF-R cleavage, and found that this process is blocked by a synthetic inhibitor of matrix metallo-proteinase activity (MMP), BB-2275. Inhibition of TNF-R cleavage was observed in a number of different cell types, as detected by retention of surface bound TNF receptor and by less sTNF-R released into the cell supernatant. The augmentation of surface TNF-R expression was of biological relevance as TNF alpha-mediated necrosis of human KYM.1D4 rhabdosarcoma cells was enhanced approximately 15-fold in the presence of BB-2275. The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). Paradoxically, despite the reduction in soluble TNF alpha levels, the production of IL-1 beta, IL-6, and IL-8, cytokines whose production was previously demonstrated to be inhibited by the addition of neutralizing anti-TNF alpha antibody were not down-regulated by BB-2275. These results raise the interesting possibility that a close relationship exits between the enzyme(s) which process membrane-bound TNF alpha, and those involved in surface TNF-R cleavage. Furthermore our observations suggest that hydroxamate inhibitors of MMP activity which block TNF alpha secretion and TNF-R cleavage may not modulate down-stream effects of TNA alpha, and as such suggest that the precise specificity of these compounds will be highly relevant to their clinical efficacy in inflammatory diseasesThis publication has 46 references indexed in Scilit:
- TNF Inhibitors are Produced Spontaneously by Rheumatoid and Osteoarthritic Synovial Joint Cell Cultures: Evidence of Feedback Control of TNF ActionScandinavian Journal of Immunology, 1995
- TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cellsCytokine, 1994
- Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytesEuropean Journal of Immunology, 1994
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- Immunoregulatory role of interleukin 10 in rheumatoid arthritis.The Journal of Experimental Medicine, 1994
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992
- A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinasesFEBS Letters, 1992
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Shedding of tumor necrosis factor receptors by activated human neutrophils.The Journal of Experimental Medicine, 1990
- Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamilyCell, 1990